Your session is about to expire
← Back to Search
Vitamin
Vitamin C for Insulin Resistance
Phase 1 & 2
Recruiting
Led By Seth Holwerda, PhD
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Middle-aged: 35-65 years
Be older than 18 years old
Must not have
Currently taking a statin or antihypertension medication
History of vascular disease (e.g., bypass, stroke)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 120 minutes
Summary
This trial is testing if Vitamin C can improve blood vessel health and lower blood pressure in obese adults who have difficulty processing sugar. These individuals often have high blood pressure and a higher risk of heart disease. Vitamin C might help by making blood vessels healthier and calming the nerves that control them. Vitamin C has been studied for its potential benefits in reducing blood pressure and improving heart health, though results have been inconsistent.
Who is the study for?
This trial is for obese adults aged 35-65 with insulin resistance. Participants must not be taking statins, antihypertension meds, or have a history of heart or vascular disease. They should stop vitamin C/E and omega-3 supplements two weeks before the study.
What is being tested?
The study tests how well Vitamin C (ascorbic acid solution) can improve blood vessel function in comparison to saline in people with insulin resistance. It aims to see if Vitamin C can lower high blood pressure by improving vascular health.
What are the potential side effects?
Potential side effects from ascorbic acid may include digestive discomfort, such as stomach cramps or diarrhea, and possibly an increased risk of kidney stones if taken in large doses over long periods.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 35 and 65 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am currently on medication for high cholesterol or high blood pressure.
Select...
I have a history of vascular disease.
Select...
I have a history of heart disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 120 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~120 minutes
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Efficacy of infusion of ascorbic acid
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Ascorbic acid infusionActive Control1 Intervention
Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the University of Kansas (KU) Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a "drip-infusion" of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min.
Group II: Placebo infusionPlacebo Group1 Intervention
Saline will be administered over 2 hours
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for cardiovascular disease (CVD) include statins, GLP-1-based therapies, and vitamin C. Statins work by inhibiting the enzyme HMG-CoA reductase, which reduces cholesterol synthesis in the liver, thereby lowering LDL cholesterol levels and improving endothelial function.
GLP-1-based therapies help reduce atherosclerosis by lowering total cholesterol, LDL cholesterol, and triglycerides, and improving endothelial function. Vitamin C, an antioxidant, enhances blood vessel function and reduces blood pressure by improving endothelial function and reducing oxidative stress.
These mechanisms are crucial for CVD patients as they help prevent the progression of atherosclerosis, reduce the risk of heart attacks and strokes, and improve overall cardiovascular health.
Effects of colestipol-niacin therapy on human femoral atherosclerosis.Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.
Effects of colestipol-niacin therapy on human femoral atherosclerosis.Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.
Find a Location
Who is running the clinical trial?
University of Kansas Medical CenterLead Sponsor
508 Previous Clinical Trials
174,461 Total Patients Enrolled
Seth Holwerda, PhDPrincipal Investigator - University of Kansas Medical Center
University of Kansas Medical Center
Share this study with friends
Copy Link
Messenger